Last reviewed · How we verify

Fentanyl, propofol

The Affiliated Hospital of Qingdao University · FDA-approved active Small molecule Quality 2/100

Fentanyl and propofol, marketed by The Affiliated Hospital of Qingdao University, are established anesthetics with a strong presence in the healthcare sector. A key strength is the protection of their composition patent, which expires in 2028, providing a significant barrier to generic competition. The primary risk is the lack of revenue data and key trial results, which may limit investor confidence and market valuation.

At a glance

Generic nameFentanyl, propofol
SponsorThe Affiliated Hospital of Qingdao University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: